Latest:
Research highlights since Lp(a) Forum launch

In the 12 months since Lp(a) Forum was launched in April 2024, we have seen some remarkable progress in the field of Lp(a) research. As scientists, we now understand a lot more about the atherogenicity of Lp(a) particles, and the specific lipid components, such as diacylglycerols (DG) and lysophosphatidic acid (LPA), that contribute to their atherogenicity.
Dr Elias Björnson, University of Gothenburg, Sweden, discusses some memorable scientific advances and clinical developments in the field of Lp(a) research and looks forward to further investigations that will translate these findings into real world practice.
First Closed Scientific Expert Meeting of the Editorial Board




About Lp(a) Forum

The Lp(a) Forum is a new, independent, non-profit, expert-led, global initiative providing clinicians and researchers worldwide with open access, peer-reviewed resources devoted to the exciting and rapidly developing area of Lp(a) science and therapeutics.
The Forum brings together internationally-recognised experts from the scientific and clinical communities who are committed to developing awareness, knowledge and understanding of the importance of Lp(a) as an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis, even when LDL-cholesterol levels are low… Read more
Free Membership
Lp(a) Forum Co-Chair, Professor John Chapman, invites you to join Lp(a) Forum for open access to multimedia educational resources about Lp(a) science, management and research.
Why do we need this Forum?
In recent years, unequivocal evidence has been published supporting Lp(a) as a target for lipid lowering therapies to reduce cardiovascular risk in individuals with significantly elevated Lp(a) levels. Innovative Lp(a) targeted therapies are in development and there is now an urgent need for reliable, accessible scientific and clinical information about Lp(a) for the clinical and scientific community that is appropriate for all levels of expertise and interest.
Back to Basics
Back to Basics summarises current thinking on key aspects of Lp(a) science and management
What is Lp(a)

Lp(a) is a plasma lipoprotein that consists of an LDL-like particle in which apolipoprotein B100 is covalently linked to the plasminogen-like protein…
Read more
Lp(a) measurement

Lp(a) level is measured as Lp(a) particle number (nmol/L) or Lp(a) mass concentration (mg/dL), and levels ≥100/125 nmol/L (≥50 mg/dL) are …
Read more
Why test Lp(a)?

Professor Keith Ferdinand, Tulane University School of Medicine, New Orleans, USA, discusses the advantages of Lp(a) testing for patients and their families…
Read more
Lp(a) and CVD

Elevated Lp(a) is associated with increased risk of coronary heart disease, ischaemic stroke, peripheral artery disease, heart failure, aortic stenosis and mortality …
Read more
Lp(a) therapies

No Lp(a) targeted therapies have been approved, but experts agree that intensive management of other risk factors is important in individuals with elevated …
Read more
Journal Updates

Brussels Declaration calls for Lp(a) testing in CV health plans The Brussels International Declaration on Lp(a) testing and management has been published in Atherosclerosis …

Lp(a) testing is cost effective in high income countries A new cost effectiveness analysis of Lp(a) testing for primary prevention, carried out …

Waist-to-hip ratio modifies Lp(a) risk of ASCVD Waist-to-hip ratio (WHR) significantly modifies the risk of ASCVD associated …

UK lipid guidance recommends Lp(a) measurement in enhanced lipid profiling New UK lipid guidance recommends Lp(a) measurement to be included in enhanced lipid profiling …

Apo(a) isoform size affects Lp(a) response to lipid lowering therapy People with larger apo(a) size have the greatest reduction in Lp(a) level in response to …
Latest Congress Highlights

Delegates at the recent 93rd EAS Congress were left in no doubt of the importance of Lp(a) as a key risk factor for atherosclerotic cardiovascular disease (ASCVD), with new data from a major US study showing Lp(a) as a driver of recurrent ASCVD events. Further presentations linked Lp(a) with coronary events in the presence of few if any traditional risk factors, and with vulnerable plaques. Researchers also reinforced the importance of Lp(a) testing as early in life as possible and provided reassuring evidence that low Lp(a) levels are not linked to dementia.
Upcoming Congress

ESC 2025
29 Aug – 1 Sept, Madrid, Spain.
Other Congress News

At this year’s American College of Cardiology Scientific Sessions in Chicago, USA (29-31 March 2025), Lp(a) research highlights included results of the Phase 2 ALPACA trial of lepodisiran, the impact of Lp(a) testing on cardiovascular (CV) event reduction, and reasons why testing is not more widespread. In addition, researchers presented data showing the importance of Lp(a) in diabetic retinopathy, the effects of Lp(a) on plaque, and clues that inhibition of Lp(a) oxidation may have contributed to the CV benefits shown in REDUCE-IT in patients with hypertriglyceridaemia.
Video Library
International experts discuss hot topics on all aspects of the epidemiology, genetics and pathophysiology of Lp(a).